| Identification | More | [Name]
Argatroban | [CAS]
141396-28-3 | [Synonyms]
(2r,4r)-1-[(2s)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid
(2r,4r)-4-methyl-1-[n-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-l-arginyl]-2-piperidinecarboxylic acid
ARGATROBAN
GN1600
(2R,4R)-1-[N2-3-(methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl]-4-methyl-2-piperidinecarboxylic acid monohydrate
(2R,4R)-1-[(2S)-5-[(Aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid
Argatroban
Argatroban Monohydrate | [Molecular Formula]
C23H38N6O6S | [MDL Number]
MFCD00895735 | [Molecular Weight]
526.65 | [MOL File]
141396-28-3.mol |
| Hazard Information | Back Directory | [Originator]
Acova,SmithKline Beecham | [Uses]
Argatroban monohydrate has been used as a thrombin-selective inhibitor in the thrombin assay of platelet poor plasma samples. It may be used as a standard in gradient reversed-phase liquid chromatography coupled with high-resolution multistage mass spectrometry (LC/HR-MSn) for photoproducts fragmentation analysis and as a thrombin inhibitor competitive assay with fullerene-based C60 nanoparticle (NPs). | [Uses]
Anticoagulant. | [Manufacturing Process]
To a stirred solution of 28.3 g of NG-nitro-N2-(tert-butoxycarbonyl)-L-arginine
in 450 ml of dry tetrahydrofuran were added in turn 9.0 g of triethylamine
and 12.2 g of isobutyl chloroformate while keeping the temperature at -20°C.
After 10 minutes, to this was added 15.2 g of ethyl 4-methyl-2-
piperidinecarboxylate and the mixture was stirred for 10 minutes at -20°C. At
the end of this period, the reaction mixture was warmed to room
temperature. The solvent was evaporated and the residue taken up in 400 ml
of ethyl acetate, and washed successively with 200 ml of water, 100 ml of 5%
sodium bicarbonate solution, 100 ml of 10% citric acid solution and 200 ml of
water. The ethyl acetate solution was dried over anhydrous sodium sulfate.
The solution was evaporated to give 31.5 g (75 %) of ethyl 1-[NG-nitro-N2-
(tert-butoxycarbonyl)-L-arginyl]-4-methyl-2-piperidinecarboxylate in the form
of a syrup.
To a stirred solution of 30 g of ethyl 1-[NG-nitro-N2-(tert-butoxycarbonyl)-Larginyl]-
4-methyl-2-piperidinecarboxylate in 50 ml of ethyl acetate was added
80 ml of 10% dry HCl-ethyl acetate at 0°C. After 3 hours, to this solution was
added 200 ml of dry ethyl ether to precipitate a viscous oily product. This was
filtered and washed with dry ethyl ether to give ethyl 1-[NG-nitro-L-arginyl]-4-
methyl-2-piperidinecarboxylate hydrochloride as an amorphous solid.
To a stirred solution of ethyl 1-(NG-nitro-L-arginyl)-4-methyl-2-
piperidinecarboxylate hydrochloride in 200 ml of chloroform were added in
turn 18.5 g of triethylamine, and 14.7 g of 3-methyl-8-quinolinesulfonyl
chloride at 5°C, and stirring was continued for 3 hours at room temperature.
At the end of this period, the solution was washed twice with 50 ml of water.
The chloroform solution was dried over anhydrous sodium sulfate. Upon
evaporation of the solvent, the residue was chromatographed on 50 g of silica
gel packed in chloroform, washed with chloroform and eluted with 3%
methanol-chloroform. The fraction eluted from 3% methanol-chloroform was
evaporated to give 32.1 g (91%) of ethyl 1-[NG-nitro-N2-(3-methyl-8-
quinolinesulfonyl)-L-arginyl]-4-methyl-2-piperidinecarboxylate in the form of
an amorphous solid.
A solution of 30 g the above product in 100 ml of ethanol and 100 ml of 1 N
sodium hydroxide solution was stirred for 24 hrs at room temperature. At the
end of this period, the solution was neutralized with 1 N hydrochloric acid and
then concentrated to 70 ml. The solution was adjusted to pH=11 with 1 N
sodium hydroxide solution, washed three times with 100 ml of ethyl acetate,
acidified with 1 N hydrochloric acid and then extracted three times with 100
ml of chloroform. The combined chloroform solution was dried over anhydrous
sodium sulfate and evaporated to give 28.0 g (97%) of 1-[NG-nitro-N2-(3-
methyl-8-quinolinesulfonyl)-L-arginyl]-4-methyl-2-piperidinecarboxylic acid as
an amorphous solid. IR (KBr): 3,300, 1,720, 1,630 cm-1.
To a solution of 3.00 g of 1-[NG-nitro-N2-(3-methyl-8-quinolinesulfonyl)-Larginyl]-
4-methyl-2-piperidinecarboxylic acid in 50 ml of ethanol was added
0.5 g of palladium black and then the mixture was shaken under 10 kg/cm2
H2 pressure at 100°C for 8 hrs. At the end of this period, the ethanol solution
was filtered to remove the catalyst and evaporated to give 2.50 g (90%) of 1-
[N2-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl]-4-methyl-2-
piperidinecarboxylic acid as an amorphous solid. IR (KBr): 3,400, 1,620,
1,460, 1,380 cm-1.
| [Brand name]
Novastan (Mitsubishi
Chemical Corporation, Japan). | [Therapeutic Function]
Anticoagulant | [General Description]
Argatroban anticoagulant is synthesized from L-arginine and photodegrades under light exposure. | [Biochem/physiol Actions]
Argatroban is a potent, seletive, univalent direct inhibitor of thrombin. It directly inhibits thrombin by binding only to its active site (thus univalent) as compared to Bivalent DTIs (hirudin and analogs) which bind both to the active site and exosite 1. | [Enzyme inhibitor]
This anticoagulant (FW = 508.64 g/mol; CAS 74863-84-6), also named
(2R,4R) -4-methyl-1-N2-[ (3-methyl-1,2,3,4-tetrahydro-8-quinolilyl) sulfon-
yl]-L-arginyl-2-piperidine carboxylic acid, Novastan?, and MD-805, is a
direct thrombin inhibitor (1-11) that is an effective treatment for heparin-
induced thrombocytopenia (HIT), an immunoglobulin-mediated adverse
drug reaction characterized by platelet activation, thrombocytopenia, and a
high risk of thrombotic complications among patients who are receiving or
have recently received heparin. HIT is an autoimmune-like disorder, with
the target antigen a multimolecular complex of the “self” protein, Platelet
Factor-4, and heparin. Continued use of heparin is ill-advised and
dangerous. Argatroban is also indicated for the treatment of heparin-
induced thrombocytopenia and thrombosis syndrome (HITTS), an immune-
mediated response to the administration of heparin that results in life-
threatening thrombosis. Argatroban is one of four FDA-approved
parenteral direct thrombin inhibitors, the others being lepirudin, desirudin,
and bivalirudin. Argatroban is metabolized in the liver (t1/2 = ~50 min).
Other DTI’s include recombinant hirudins, bivalirudin, and ximelagatran,
either alone or in combination with melagatran. Argatroban is a
significantly weaker inhibitor of trypsin, K = 4.3 μM, plasmin (K =
ii
800 μM), coagulation factor Xa, and plasma kallikrein (Ki = 2 mM).
Commercial sources often supply a mixture of 21 (R) and 21 (S)
Diastereoisomers. The latter is more potent. |
|
|